Charles Schwab Investment Management Inc. Buys 1,657 Shares of Grifols, S.A. (NASDAQ:GRFS)

Charles Schwab Investment Management Inc. grew its stake in Grifols, S.A. (NASDAQ:GRFS) by 5.3% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 33,200 shares of the biotechnology company’s stock after buying an additional 1,657 shares during the period. Charles Schwab Investment Management Inc.’s holdings in Grifols were worth $247,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently made changes to their positions in GRFS. Blue Trust Inc. grew its position in Grifols by 344.4% during the fourth quarter. Blue Trust Inc. now owns 8,697 shares of the biotechnology company’s stock valued at $65,000 after acquiring an additional 6,740 shares during the last quarter. China Universal Asset Management Co. Ltd. boosted its stake in shares of Grifols by 10.2% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 25,867 shares of the biotechnology company’s stock valued at $192,000 after purchasing an additional 2,403 shares in the last quarter. R Squared Ltd purchased a new stake in shares of Grifols in the 4th quarter valued at $28,000. Helikon Investments Ltd bought a new position in shares of Grifols during the 4th quarter valued at $580,000. Finally, GAMMA Investing LLC raised its position in Grifols by 44.5% in the 4th quarter. GAMMA Investing LLC now owns 4,959 shares of the biotechnology company’s stock worth $37,000 after purchasing an additional 1,527 shares during the period.

Analyst Upgrades and Downgrades

Separately, Morgan Stanley assumed coverage on Grifols in a research note on Wednesday, February 12th. They issued an “overweight” rating for the company.

Grifols Price Performance

GRFS opened at $6.96 on Wednesday. The company has a debt-to-equity ratio of 1.11, a quick ratio of 0.79 and a current ratio of 2.26. The stock has a market capitalization of $4.79 billion, a PE ratio of 5.95 and a beta of 0.35. The stock’s 50 day moving average price is $7.55 and its 200-day moving average price is $8.01. Grifols, S.A. has a 52-week low of $5.79 and a 52-week high of $9.96.

About Grifols

Grifols, SA operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand’s disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer’s disease.